TipRanks
Go Ultimate55% OFF

RMH Holdings Limited (8437) AI Stock Analysis

Top Page

HK:8437

RMH Holdings Limited

(HKEX:8437)

Select Model
Rating:41Neutral
Price Target:HKD 0.24â–¼(-4.40% Downside)
Action:reiterated
Date:01/21/26

The score is driven primarily by very weak financial performance (declining revenue, persistent losses, negative equity, and weak cash generation). Technical indicators are also unfavorable (price below key short-term averages, negative MACD, very low RSI). Valuation is constrained by negative earnings and no dividend data.

Positive Factors
Diversified Business MixA multi‑sector investment model spreads revenue sources across real estate rents, management fees and tech dividends. That structural diversification can smooth cash flow cycles, enable capital allocation across opportunities, and reduce single‑sector exposure over months.
Negative Factors
Negative Shareholders' EquityNegative equity is a structural solvency red flag that limits access to conventional capital, increases refinancing and covenant risk, and may force asset sales or recapitalization. This weakens long‑term financial flexibility and heightens execution risk over months.

RMH Holdings Limited (8437) vs. iShares MSCI Hong Kong ETF (EWH)

-25%0%25%50%75%100%125%150%HK:8437+47.06%EWH+7.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
HKD 16.65M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-0.8
Beta (1Y)
0.39
Revenue Growth
―
EPS Growth
―
Country
Hong Kong
Employees
45
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

RMH Holdings Limited Business Overview & Revenue Model

Company Description

RMH Holdings Limited, an investment holding company headquartered in Singapore and incorporated in 2017, delivers a diverse range of medical, dermatological, and aesthetic products and services across Singapore, Hong Kong, and international markets....

RMH Holdings Limited Financial Statement Overview

Summary

Very weak fundamentals: multi-year revenue decline with significant negative EBIT and net income, negative shareholders’ equity indicating elevated solvency risk, and operating/free cash flow that has improved only modestly and remains insufficient versus needs.

Income Statement

25Negative

Balance Sheet

20Very Negative

Cash Flow

30Negative
Financial statement breakdown
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.22M5.04M3.18M4.24M238.00K8.24M
Gross Profit-1.01M3.15M1.54M-2.51M-2.05M5.12M
EBITDA-3.79M-2.60M-5.00M-4.64M-2.59M-4.26M
Net Income-5.06M-3.51M-6.75M-18.65M-8.79M-9.27M
Balance Sheet
Total Assets4.92M3.97M4.15M12.40M18.91M20.49M
Cash, Cash Equivalents and Short-Term Investments557.00K566.00K306.00K2.12M2.75M4.93M
Total Debt4.10M4.28M258.00K5.35M11.06M11.76M
Total Liabilities29.12M28.38M16.67M18.69M14.34M14.96M
Stockholders Equity-19.27M-19.50M-12.41M-6.29M4.57M5.53M
Cash Flow
Free Cash Flow-8.51M113.00K368.00K-6.41M-7.33M-6.64M
Operating Cash Flow-8.50M114.00K781.00K-5.09M-6.13M-4.51M
Investing Cash Flow9.91M142.00K1.52M-3.28M-506.00K-6.69M
Financing Cash Flow1.59M-4,000-2.46M6.65M3.82M3.47M

RMH Holdings Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price0.25

Price Trends

50DMA0.25Negative
100DMA0.25Negative
200DMA0.26Negative

Market Momentum

MACD-0.00Negative
RSI34.73Neutral
STOCH-0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8437, the sentiment is Negative. The current price of 0.25 is below the 20-day moving average (MA) of 0.25, below the 50-day MA of 0.25, and below the 200-day MA of 0.26, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 34.73 is Neutral, neither overbought nor oversold. The STOCH value of -0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:8437.

RMH Holdings Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:8437 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:2373HK:237379OutperformHKD 4.17B8.8131.63%4.33%22.71%43.58%
HK:2135HK:213555NeutralHKD 62.39M3.9412.17%―36.68%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:8161HK:816144NeutralHKD 28.70M-8.86-32.49%―-21.61%-140.20%
HK:8437HK:843741NeutralHKD 16.65M-0.7721.98%―――
HK:8307HK:830737UnderperformHKD 60.30M64.2819.79%―6.13%―

* Healthcare Sector Average

Performance Comparison

0%50%100%HK:8437HK:1947HK:2135HK:2373HK:8161HK:8307Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
HK:8437 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:8437RMH Holdings Limited0.250.0847.06%
HK:1947Meihao Medical Group Co., Ltd.0.470.1755.00%
HK:2135Raily Aesthetic Medicine International Holdings Limited0.11-0.00-3.45%
HK:2373Beauty Farm Medical & Health Industry, Inc.16.62-12.33-42.60%
HK:8161MediNet Group Ltd.0.690.0915.00%
HK:8307Medicskin Holdings Ltd.0.15-0.03-15.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Jan 21, 2026